Sandra Van Lint

6PUBLICATIONS
64CO-AUTHORS
Medical devicesCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteinsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 10, 2026
Inherited human TFIIIA deficiency disrupts T cell development.

|May 07, 2026
Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy.

|Nov 13, 2021
Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication.

Bram Van Den Eeckhout, Leander Huyghe, Sandra Van Lint

|Mar 04, 2021
mRNA in cancer immunotherapy: beyond a source of antigen.

Lien Van Hoecke, Rein Verbeke, Heleen Dewitte

|Jul 28, 2020
Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.

Bram Van Den Eeckhout, Lien Van Hoecke, Elianne Burg

|Aug 26, 2018
Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes.

Lien Van Hoecke, Sandra Van Lint, Kenny Roose

Pageof 1

Frequent Collaborators

2 joint publications

Lien Van Hoecke

2 joint publications

Xavier Saelens

2 joint publications

Bram Van Den Eeckhout

2 joint publications

Jan Tavernier